TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01623180

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofreedom™ Drug Coated Stent (DCS)
Description: Biofreedom DCS implantation in high risk bleeding patients followed by 1 month DAPT

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gazelle™ Bare Metal Coronary Stent (BMS)
Description: Gazelle BMS implantation in high risk bleeding patients followed by 1 month DAPT
Study: NCT03103087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Relugolix (40 mg) tablet administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Relugolix (40 mg) tablet administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol/norethindrone acetate
Description: E2 (1.0 mg)/NETA (0.5 mg) co-formulated capsule administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol/norethindrone acetate
Description: E2 (1.0 mg)/NETA (0.5 mg) co-formulated capsule administered orally once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Relugolix placebo
Description: Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Estradiol/norethindrone acetate placebo
Description: E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the capsule containing E2/NETA in size, shape, color, and odor.
Study: NCT04252794

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Splenic artery ligation
Description: Splenic artery will be ligated just after takeoff from coeliac trunk at the level of body of pancreas

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: Splenic artery is not ligated despite the presence of portal hyperperfusion
Study: NCT02924467

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2 Notices
Description: 2 Reminder notifications via autodialer

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3 Notices
Description: 3 Reminder notifications via autodialer
Study: NCT03374709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxtellar XR 150Mg Extended Release Tablet
Description: Oxtellar XR
Study: NCT02854202

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm1: Whey protein
Description: Arm1: Whey protein:The participants will consume 42 g protein, namely from Whey protein in the breakfast

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2 Breakfast- other proteins
Description: Arm 2 Breakfast- other proteins: The participants will be assigned to 42 g protein of other protein sources at breakfast

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Arm 3 Breakfast- low protein
Description: Arm 3: Low protein' :The participants will consume 22 g protein at breakfast
Study: NCT01881711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ShuntCheck-Micro-Pumper (SCMP)
Description: ShuntCheck uses thermal dilution to detect flow in CSF shunts. CSF is cooled transcutaneously with an ice pack and ShuntCheck's thermosensor detects a temperature drop due to CSF flow downstream of the ice. Micro-Pumper is a handheld device which vibrates the shunt valve to generate a temporary increase in CSF flow in patent but temporarily non-flowing shunts. This flow increase can be detected by ShuntCheck.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ShuntCheck-Micro-Pumper (SCMP)
Description: ShuntCheck uses thermal dilution to detect flow in CSF shunts. CSF is cooled transcutaneously with an ice pack and ShuntCheck's thermosensor detects a temperature drop due to CSF flow downstream of the ice. Micro-Pumper is a handheld device which vibrates the shunt valve to generate a temporary increase in CSF flow in patent but temporarily non-flowing shunts. This flow increase can be detected by ShuntCheck.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ShuntCheck-Micro-Pumper (SCMP)
Description: ShuntCheck uses thermal dilution to detect flow in CSF shunts. CSF is cooled transcutaneously with an ice pack and ShuntCheck's thermosensor detects a temperature drop due to CSF flow downstream of the ice. Micro-Pumper is a handheld device which vibrates the shunt valve to generate a temporary increase in CSF flow in patent but temporarily non-flowing shunts. This flow increase can be detected by ShuntCheck.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Imaging
Description: Imaging of ventricle size

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Imaging
Description: Imaging of ventricle size

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Imaging
Description: Imaging of ventricle size

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imaging
Description: Imaging of ventricle size

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imaging
Description: Imaging of ventricle size
Study: NCT02231502

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vegetable-based convenience food

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vegetable meal
Study: NCT01243762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalotuzumab
Description: Administered intravenously (IV) once weekly in 28-day cycles for a maximum of 6 months of study therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalotuzumab
Description: Administered intravenously (IV) once weekly in 28-day cycles for a maximum of 6 months of study therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalotuzumab
Description: Administered intravenously (IV) once weekly in 28-day cycles for a maximum of 6 months of study therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalotuzumab
Description: Administered intravenously (IV) once weekly in 28-day cycles for a maximum of 6 months of study therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalotuzumab
Description: Administered intravenously (IV) once weekly in 28-day cycles for a maximum of 6 months of study therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalotuzumab
Description: Administered intravenously (IV) once weekly in 28-day cycles for a maximum of 6 months of study therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalotuzumab
Description: Administered intravenously (IV) once weekly in 28-day cycles for a maximum of 6 months of study therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0752
Description: Administered orally (PO) weekly in 28-day cycles for a maximum of 6 months of study therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0752
Description: Administered orally (PO) weekly in 28-day cycles for a maximum of 6 months of study therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: Administered PO daily for 5 consecutive days per week in 28-day cycles for a maximum of 6 months of study therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: Administered PO weekly in 28-day cycles for a maximum of 6 months of study therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: Administered PO weekly in 28-day cycles for a maximum of 6 months of study therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: Administered PO weekly in 28-day cycles for a maximum of 6 months of study therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: Administered PO weekly in 28-day cycles for a maximum of 6 months of study therapy
Study: NCT03133429

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MER
Description: carotid artery stenting
Study: NCT01642472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal Acetate - open label
Description: Ulipristal Acetate (PGL4001) tablets 10mg orally daily for 3 months (84 days) for each treatment course. There are four 3-month treatment courses in this study.
Study: NCT00998166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 1. Pre-hydration for 1-1/2 hours at 250 ml/hour~2. Pemetrexed 500 mg/m2 IV over 10 minutes~3. Return to hydration for 30 minutes at 250 ml/hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 4. Cisplatin 75mg/m2 IV over 60-120 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5. Bevacizumab 15mg/kg IV over 90 minutes
Study: NCT02305199

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hartmann's solution
Description: Hartmann's solution containing 200 mg/L of calcium chloride, 300 mg/L of potassium chloride, 6 g/L of Sodium chloride, 3.1 g/L of Sodium lactate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Fluid containing Sodium chloride 9 g/L
Study: NCT00396357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Study: NCT04537312

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted Nipple Sparing Mastectomy
Description: Under RNSM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: ancillary correlative

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RNSM
Description: Robot-assisted Nipple Sparing Mastectomy
Study: NCT03454191

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: Injection of local anaesthetics below the erector spinae muscle after induction of anaesthesia

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: No injection
Description: No injection
Study: NCT00475657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m2, intravenous (IV), every 21 days x 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m2, intravenous (IV), every 21 days x 6 cycles
Study: NCT04717310

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SHR0302 Ointment
Description: SHR0302 Ointment Twice a day (BID)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SHR0302 Ointment
Description: SHR0302 Ointment Twice a day (BID)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SHR0302 Ointment
Description: SHR0302 Ointment Twice a day (BID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Twice a day (BID)
Study: NCT03612869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYS-SAF302
Description: Treatment will involve direct injections of the investigational product into both sides of the brain through image-guided tracks, in a single neurosurgical session.
Study: NCT03276858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRN00808
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRN00808
Description: Investigational drug

Intervention type: DRUG
Group type: OTHER
Intervention: CRN00808
Description: Investigational drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Solution
Description: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam oral solution
Description: Midazolam as part of the drug-drug interaction arm of the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo
Study: NCT04505592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: First 20 patients randomized to treatment arm will receive 0.25 mg/kg of tenecteplase. Next 20 patients randomized to treatment arm will receive 0.50 mg/kg of tenecteplase. Both will receive concomitant heparin to maintain activated partial thromboplastin time between 2.0 and 2.5 upper limit of normal.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo with concomitant heparin to maintain activated partial thromboplastin time between 2.0 and 2.5 upper limit of normal.
Study: NCT05188768

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Concentrated Growth Factor Membrane
Description: Concentrated growth factor is produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Concentrated Growth Factor Membrane
Description: Concentrated growth factor is produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Fibrin
Description: Platelet Rich Fibrinis produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Fibrin
Description: Platelet Rich Fibrinis produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
Study: NCT02883400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: spironolactone 25 mg up to 50 mg
Study: NCT04284046

Intervention type: OTHER
Intervention: CT score
Description: CT score = normal lung tissue (%) ×1 + GGO (%) ×2 + consolidation (%) ×3

Intervention type: OTHER
Intervention: CT score
Description: CT score = normal lung tissue (%) ×1 + GGO (%) ×2 + consolidation (%) ×3
Study: NCT00413322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belinostat
Description: 300, 600, or 1000 mg/m2 belinostat IV for 5 days every 21 days starting with cycle 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: 250, 500, 750, or 1000 mg/m2/d of 5-FU starting with cycle 2 onwards in combination with belinostat. Starting on day 2, 5-FU is administered as a continuous 96 hour infusion.
Study: NCT03796572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Regional anesthesia protocol of open reduction percutaneous pinning of lateral condyle humerus fracture Ropivacaine

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Puncture Wound and Dressing
Description: No regional anesthesia is given for open reduction percutaneous pinning of lateral condyle humerus fracture
Study: NCT01521975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine, Adefovir dipivoxil
Description: All patients will take Telbivudine 600 mg PO daily from baseline. Some patients will take Adefovir dipivoxil 10 mg PO daily if they meet the criteria of adding Adefovir dipivoxil.
Study: NCT03560765

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MED
Description: Training in the use of mainstream electronic devices with accessibility options

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MED
Description: Training in the use of mainstream electronic devices with accessibility options

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Buddy
Description: A buddy who will meet with the participant regularly for social interaction, and assistance with use of any MED purchased

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buddy
Description: A buddy who will meet with the participant regularly for social interaction, and assistance with use of any MED purchased
Study: NCT03557073

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postoperative phone call
Description: The intervention is a phone call on the day following surgery.
Study: NCT03710824

Intervention type: DRUG
Intervention: Nintedanib
Description: diagnosed IPF patients initiating treatment with nintedanib
Study: NCT01405989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darexaban
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darexaban
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoconazole
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoconazole
Description: oral
Study: NCT03628573

Intervention type: DEVICE
Group type: OTHER
Intervention: repetitive transcranial magnetic stimulation (MagPro X100).
Description: accelerated rTMS.

Intervention type: DEVICE
Group type: OTHER
Intervention: Intermittent Theta burst stimulation ( iTBS)
Study: NCT03829995

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Drug counseling
Description: Participants can contact a hospital pharmacy department by phone or mail and ask questions regarding drug-related issues.
Study: NCT01260064

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open appendectomy
Description: The subjects will have traditional open appendectomy procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic appendectomy with metal endoclips
Description: The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by metal endoclips.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic appendectomy with suture ligation
Description: The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by intracorporeal suture ligation.
Study: NCT04585828

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phototherapy with double sided fiber optic pads with blue light at irradiance 30 uW/cm2/nm using Bili Cocoon
Description: The baby will be treated with Bilicocoon for 24 hours. Decrease of total serum biliurubin will be evalueated hereafter.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phototherapy from above using NeoBlue at irradiance of 30 uW/cm2/nm
Description: The baby will be treated with phototherapy from above for 24 hours. Decrease of total serum bilirubin will be evaluated hereafter.
Study: NCT02095834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00207116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: IV solution, IV, 400 mg/m2 initial dose followed by weekly doses of 250 mg/m2, Weekly, until disease progression.
Study: NCT03045107

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic right colectomy with intracorporeal ileocolic anastomosis (IIA)
Description: After complete right colon mobilization and ileocolic and right colic vessels ligation, the proximal transverse colon and the terminal ileum are transected with a laparoscopic EndoGIA TM stapler (Covidien Medtronic). The antimesenteric side of the stapled ends of the transverse colon and terminal ileum are approximated by a stay suture tied intracorporeally and then held by the assistant. An antimesenteric enterotomy and an antimesenteric colotomy are made about 10 cm distal to the stapled ends of the transverse colon and terminal ileum, respectively. A side-to-side anastomosis is fashioned with a laparoscopic EndoGIA TM stapler (Covidien Medtronic). The enterotomies are then closed by two layers of reabsorbable sutures tied intracorporeally. The specimen is delivered through a small Pfannenstiel or a median incision. A big dressing covering all incisions will be applied, similar to that used for the EIA group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic right colectomy with extracorporeal ileocolic anastomosis (EIA)
Description: After complete right colon mobilization and ileocolic and right colic vessels ligation, the terminal ileum, right colon, and proximal transverse colon are exteriorized for bowel division through a small midline skin incision in the upper abdomen. A primary ileocolic side-to-side handsewn or mechanical (with GIA stapler - Covidien Medtronic) anastomosis is fashioned and the bowel returned to the abdominal cavity. After reinduction of pneumoperitoneum, the lack of twists of the ileocolic anastomosis is checked. A big dressing covering all incisions will be applied.
Study: NCT04359758

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive Streamlined Genetic Education and Testing
Description: This intervention consists of the proactive delivery of genetic education print materials followed by streamlined and facilitated access to genetic testing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: This intervention consists of a standard genetic referral letter that notified the participant that he qualified for genetic referral, recommends the scheduling of a genetic counseling session and provides a telephone number for scheduling.
Study: NCT01135251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimiracetam
Description: 400 mg capsules for oral use to be administered twice a day for a total of 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: capsules containing 400 mg of inert material will be orally administered twice a day, one pill for 2 weeks, 2 pills for other 2 weeks and 4 pills for the last 4 weeks.
Study: NCT01429142

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: In this multi-center trial, the content of usual adherence care is not known prior to the study, but it is part of our data collection to examine the content and variability between clinics and professionals afterwards.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AIMS intervention
Description: The AIMS-intervention is counseling intervention, using MEMS-data printed in simple plots. The following intervention steps will be followed:~-Discussion of practical, tailored information about adherence -Identification of desired adherence level and motivations -Print of patients' MEMS-report and comparison with desired level -ID causes of non-adherence and how to deal with problems -Designing a tailored action plan. -Follow-up: evaluation of accomplishments, remaining problems and solutions, until desired level of adherence has been accomplished. -Formulation of goals for behavioral maintenance.~Among patients starting treatment, the same elements will be delivered but MEMS-feedback can only be incorporated in the second session (after medication has been used). Moreover, a readiness element is added at treatment initiation, where patients discuss the necessity and concerns of initiating medication and are offered the possibility to practice intake for 2 weeks with placebo.
Study: NCT00953576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocortisone